Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues...